K
Karen M. Anderson
Researcher at GlaxoSmithKline
Publications - 14
Citations - 1462
Karen M. Anderson is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Type 2 diabetes & Carvedilol. The author has an hindex of 12, co-authored 14 publications receiving 1424 citations. Previous affiliations of Karen M. Anderson include University of Massachusetts Medical School.
Papers
More filters
Journal ArticleDOI
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
George L. Bakris,George L. Bakris,George L. Bakris,Vivian Fonseca,Vivian Fonseca,Richard E. Katholi,Richard E. Katholi,Janet B. McGill,Franz H. Messerli,Franz H. Messerli,Franz H. Messerli,Robert A. Phillips,Philip Raskin,Jackson T. Wright,Rosemary Oakes,Mary Ann Lukas,Karen M. Anderson,David S.H. Bell,David S.H. Bell +18 more
TL;DR: Use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension.
Journal ArticleDOI
Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
George L. Bakris,Vivian Fonseca,Richard E. Katholi,Janet B. McGill,Franz H. Messerli,Robert A. Phillips,Philip Raskin,Rosemary Oakes,Karen M. Anderson,David S.H. Bell +9 more
TL;DR: Randomized trials comparing reninangiotensin system (RAS) blockers with -blockers demonstrate that cardiovascular outcomes are improved by RAS blockers, which maintain or improve cardiovascular outcomes by maintaining or improving glycemic control.
Journal ArticleDOI
BMP-2 gene expression and effects on human vascular smooth muscle cells.
TL;DR: The expression of BMP-2 by numerous cell types in the blood vessel wall may play a chemotactic or cochemotactic role in the smooth muscle cell response to vascular injury.
Journal ArticleDOI
The Myocardial β-Adrenergic System in Spontaneously Hypertensive Heart Failure (SHHF) Rats
TL;DR: The SHHF rat is a powerful model for use in examination of the mechanisms involved in alterations of beta-adrenergic signaling that occur in human HF, and data indicate that cardiac dysfunction is coincident with reduced betaAR density.
Journal ArticleDOI
Body Weight Changes with β-Blocker Use: Results from GEMINI
Franz H. Messerli,David S.H. Bell,Vivian Fonseca,Richard E. Katholi,Janet B. McGill,Robert A. Phillips,Philip Raskin,Jackson T. Wright,Sripal Bangalore,Fred K. Holdbrook,Mary Ann Lukas,Karen M. Anderson,George L. Bakris +12 more
TL;DR: Metoprolol tartrate was associated with increased weight gain compared to carvedilol; weight gain was most pronounced in subjects with hypertension and diabetes who were not taking insulin therapy.